Acrobiosystems Co Ltd
SZSE:301080
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.53
66.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Acrobiosystems Co Ltd
Total Liabilities & Equity
Acrobiosystems Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Acrobiosystems Co Ltd
SZSE:301080
|
Total Liabilities & Equity
ÂĄ2.8B
|
CAGR 3-Years
133%
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Total Liabilities & Equity
ÂĄ41.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Total Liabilities & Equity
ÂĄ5.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities & Equity
ÂĄ15.7B
|
CAGR 3-Years
65%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Liabilities & Equity
ÂĄ32.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities & Equity
ÂĄ54.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
38%
|
CAGR 10-Years
36%
|
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
See Also
What is Acrobiosystems Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.8B
CNY
Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Total Liabilities & Equity amounts to 2.8B CNY.
What is Acrobiosystems Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
102%
Over the last year, the Total Liabilities & Equity growth was 3%. The average annual Total Liabilities & Equity growth rates for Acrobiosystems Co Ltd have been 133% over the past three years , 102% over the past five years .